Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Updated recommendation by Touchstone Innovations

18 Oct 2017 09:38

RNS Number : 9375T
Touchstone Innovations PLC
18 October 2017
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

 

 

18 October 2017

 

Touchstone Innovations plc

 

Updated recommendation by Touchstone Innovations plc regarding IP Group plc offer (the "Offer")

Further to the announcements by IP Group plc ("IP Group"), the Board of Touchstone Innovations plc ("Touchstone" or the "Company") notes that the CMA clearance condition to the Offer has been fulfilled and that the Offer has been declared wholly unconditional as of this morning.

The Board of Touchstone also notes that IP Group has received valid acceptances in respect of 155,859,312 Touchstone shares, representing approximately 96.6844 per cent of the existing issued share capital of Touchstone, and IP Group's stated intention to commence the procedure pursuant to Chapter 3 of Part 28 of the Companies Act 2006 to compulsorily acquire the remaining Touchstone shares in respect of which the Offer is not accepted on the same terms as the Offer.

Given that the Offer is now wholly unconditional, the Board of Touchstone recommends that Touchstone shareholders who have not yet accepted the Offer now do so promptly.

Those Touchstone shareholders who accept the Offer will receive their new shares in IP Group as consideration for their Touchstone shares at an earlier date than they would as part of the compulsory acquisition procedure referred to above.

The procedure for acceptance of the IP Group Offer is set out in the IP Group offer document dated 18 July 2017, the "Update on Offer for Touchstone Innovations plc" announcement dated 18 September 2017 as well as the "Offer update - Wholly unconditional" announcement dated 18 October 2017.

IP Group has announced that the Offer will remain open until further notice and that not less than 14 calendar days' notice will be given in respect of the closure of the Offer.

The directors of Touchstone who own shares in Touchstone in their personal capacity have decided to accept the Offer in respect of their own beneficial holdings.

If you are a Touchstone shareholder and in any doubt as to the action you should take, you are recommended to seek your own financial advice immediately from your stockbroker, bank manager, solicitor, accountant, fund manager or other appropriate independent financial adviser authorised under the Financial Services and Markets Act 2000, as amended if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

 

*****

 

Enquiries:

 

Touchstone Innovations plc

020 3053 8834

Russ Cummings

J.P. Morgan Cazenove (Financial Adviser and Corporate Broker to Touchstone Innovations plc)

020 7742 4000

Michael Wentworth-Stanley/ James Robinson/ Alec Pratt

RBC Capital Markets

(Joint Corporate Broker to Touchstone Innovations plc)

020 7653 4000

Marcus Jackson

Instinctif Partners

020 7457 2020

Adrian Duffield/Melanie Toyne-Sewell/Chantal Woolcock

 

 

Further Information

 

J.P. Morgan Limited, which conducts its UK investment banking business as J.P. Morgan Cazenove ("J.P. Morgan Cazenove"), is authorised and regulated in the United Kingdom by the Financial Conduct Authority. J.P. Morgan Cazenove is acting as financial adviser exclusively for Touchstone Innovations plc and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than Touchstone Innovations plc for providing the protections afforded to clients of J.P. Morgan Cazenove or its affiliates, or for providing advice in relation to any matter referred to herein.

RBC Capital Markets is the business name used by RBC Europe Limited, which is authorised in the United Kingdom by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority and the PRA and is a subsidiary of the Royal Bank of Canada. RBC is acting as Corporate Broker to the Company.

Responsibility

The directors of Touchstone accept responsibility for the information contained in this announcement (including expressions of belief) and, to the best of the knowledge and belief of the Touchstone directors (having taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Additional Information

In accordance with Rule 26.1 of the Code, a copy of this announcement will be available at www.touchstoneinnovations.com by no later than 12 noon (London time) on the business day following this announcement. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

 

Ends

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPVVLBFDBFXFBE
Date   Source Headline
7th Jun 20177:00 amRNSForm 8 (OPD) IP Group PLC
6th Jun 201711:19 amRNSForm 8.3 - Touchstone Innovations
5th Jun 201712:46 pmRNSForm 8.3 - Touchstone Innovations Plc
1st Jun 20172:41 pmBUSForm 8.3 - Touchstone Innovations plc
1st Jun 20177:00 amRNSChairman's letter to shareholders
31st May 20175:58 pmRNSForm 8.5 (EPT/RI) - Touchstone Innovations Plc
31st May 201712:01 pmRNSForm 8.3 - Touchstone Innovations Plc
30th May 20177:00 amRNSForm 8.3 - Touchstone Innovations Plc
26th May 201712:29 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:15 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:14 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:10 pmRNSForm 8.3 - IP Group Plc
24th May 20172:55 pmRNSForm 8.3 - IP Group plc
24th May 20172:52 pmRNSForm 8.3 - Touchstone Innovations plc
24th May 20172:51 pmRNSForm 8.3 - IP Group Plc
24th May 20172:41 pmRNSForm 8.3 - Touchstone Innovations Plc
24th May 20171:15 pmRNSForm 8.3 - Touchstone Innovations Plc
24th May 201711:17 amBUSForm 8 (DD) - Touchstone Innovations Plc.
23rd May 201712:05 pmRNSUpdate on possible offer
23rd May 201711:45 amRNSForm 8.3 - Touchstone Innovations Plc
23rd May 201710:33 amRNSStatement re Possible Offer
23rd May 20177:01 amRNSStatement re Possible Offer
21st Apr 201711:21 amRNSInnovations invests £2.9m in Abzena placing
6th Apr 20177:00 amRNSInnovations provides seed funding for Cardian
31st Mar 20177:00 amRNSHalf Yearly Report
20th Mar 20177:05 amRNSInnovations supports funding round in Pulmocide
16th Mar 20177:00 amRNSInnovations invests in Cell Medica funding round
14th Mar 20177:00 amRNSInnovations supports funding round in Resolver
6th Mar 20177:00 amRNSInnovations leads £12m funding round in Garrison
28th Feb 201711:11 amRNSNotice of Results
21st Feb 20177:03 amRNSCell Medica granted FDA Fast Track designation
26th Jan 20172:00 pmRNSDirectorate Change
5th Jan 20177:00 amRNSChange of name to Touchstone Innovations plc
4th Jan 20179:00 amRNSAppointment of Joint Broker
20th Dec 201612:03 pmRNSPsiOxus signs exclusive licence agreement with BMS
28th Nov 20167:02 amRNSPortfolio company TopiVert receives IND approval
23rd Nov 20165:56 pmRNSGrant of share options
21st Nov 201612:53 pmRNSResult of AGM
28th Oct 201612:30 pmRNSProposed change of name to Touchstone Innovations
28th Oct 201612:29 pmRNSPosting of Annual Report and Notice of AGM
24th Oct 20167:12 amRNSVeryan announces completion of subject enrolment
13th Oct 20167:00 amRNSFinal Results
10th Oct 20161:02 pmRNSCrescendo Biologics sign collaboration with Takeda
6th Oct 20167:02 amRNSFirst patients dosed in TopiVert's Phase IIa study
3rd Oct 201612:10 pmRNSSale of Innovations portfolio company Permasense
21st Sep 20167:06 amRNSInnovations invests £5.1m in Artios Pharma Limited
14th Sep 201612:02 pmRNSNotice of Results
13th Sep 20164:08 pmRNSTR-1: Notification of major interest in shares
9th Sep 20161:15 pmRNSHolding(s) in Company
6th Sep 20164:17 pmRNSEdison issues update on Imperial Innovations (IVO)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.